Squadron Capital Management LLC
13F Reported Value
ⓘ$272.9M
incl. option notional
Equity Holdings
ⓘ$250.0M
Option Notional
ⓘ$23.0M
$8.2M puts / $14.8M calls
Holdings
37
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Squadron Capital Management LLC disclosed 37 positions worth $272.9M in its Form 13F-HR for Q1 2026 — $250.0M in common stock plus $23.0M of put/call option positions (reported at underlying notional value, not premium at risk), led by $RLMD (RELMADA THERAPEUTICS, INC.) at 23.6% of the equity portfolio, followed by $COGT and $KALV. During the quarter the fund opened 19 new positions and exited 15 — including a new stake in $NKTR and a full exit from $TERN. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Squadron Capital Management LLC’s Form 13F-HR filing with the SEC under CIK 2050709.
Sector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$59.0M8,474,571 sh - —
Quality
$30.3M787,492 sh - 25.9#2,530
Quality
$19.8M985,100 sh - —
Quality
$14.5M380,000 sh - —
Quality
$14.5M130,000 sh - —
Quality
$11.0M350,000 sh - 10.2
Quality
$9.0M125,000 sh - —
Quality
$8.8M1,265,231 sh - —
Quality
$8.5M3,631,000 sh - 19.7
Quality
$7.7M257,500 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 RELMADA THERAPEUTICS, INC.$RLMD | — | $59.0M | 8,474,571 |
 Cogent Biosciences, Inc.$COGT | — | $30.3M | 787,492 |
 KalVista Pharmaceuticals, Inc.$KALV | 25.9#2,530 | $19.8M | 985,100 |
 Kodiak Sciences Inc.$KOD | — | $14.5M | 380,000 |
 Abivax S.A.$ABVX | — | $14.5M | 130,000 |
 Edgewise Therapeutics, Inc.$EWTX | — | $11.0M | 350,000 |
 NEKTAR THERAPEUTICS$NKTR | 10.2 | $9.0M | 125,000 |
 Adlai Nortye Ltd.$ANL | — | $8.8M | 1,265,231 |
 Zentalis Pharmaceuticals, Inc.$ZNTL | — | $8.5M | 3,631,000 |
 Maze Therapeutics, Inc.$MAZE | 19.7 | $7.7M | 257,500 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Squadron Capital Management LLC's 37 positions.
Showing top 10 of 37 holdings.
Sector Allocation
Healthcare
$250.0M
Full Holdings — Squadron Capital Management LLC (Q1 2026)
All 37 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $RLMD | RELMADA THERAPEUTICS, INC. | $59.0M | 23.6% | +26% | — |
| 2 | $COGT | Cogent Biosciences, Inc. | $30.3M | 12.1% | +1% | — |
| 3 | $KALV | KalVista Pharmaceuticals, Inc. | $19.8M | 7.9% | +41% | 25.9 |
| 4 | $KOD | Kodiak Sciences Inc. | $14.5M | 5.8% | +30% | — |
| 5 | $ABVX | Abivax S.A. | $14.5M | 5.8% | -10% | — |
| 6 | $EWTX | Edgewise Therapeutics, Inc. | $11.0M | 4.4% | +0% | — |
| 7 | $NKTR | NEKTAR THERAPEUTICS | $9.0M | 3.6% | NEW | 10.2 |
| 8 | $ANL | Adlai Nortye Ltd. | $8.8M | 3.5% | NEW | — |
| 9 | $ZNTL | Zentalis Pharmaceuticals, Inc. | $8.5M | 3.4% | NEW | — |
| 10 | $MAZE | Maze Therapeutics, Inc. | $7.7M | 3.1% | -47% | 19.7 |
| 11 |  $SCYX | SCYNEXIS INC | $7.0M | 2.8% | NEW | — |
| 12 |  $RLAY | Relay Therapeutics, Inc. | $6.7M | 2.7% | NEW | 12.7 |
| 13 | $KALVCALL | KalVista Pharmaceuticals, Inc. | $6.3M | — | NEW | 25.9 |
| 14 |  $CCCC | C4 Therapeutics, Inc. | $5.9M | 2.4% | NEW | 6.5 |
| 15 |  $IKT | Inhibikase Therapeutics, Inc. | $5.9M | 2.4% | -17% | — |
| 16 |  $PALI | PALISADE BIO, INC. | $5.3M | 2.1% | -33% | — |
| 17 |  $EPRX | EUPRAXIA PHARMACEUTICALS INC. | $4.9M | 2.0% | +36% | — |
| 18 |  $GHRS | GH Research PLC | $4.6M | 1.8% | +3% | — |
| 19 |  $KPTIPUT | Karyopharm Therapeutics Inc. | $4.2M | — | NEW | 20.4 |
| 20 |  $PMN | ProMIS Neurosciences Inc. | $4.1M | 1.6% | NEW | — |
| 21 |  $IDYAPUT | IDEAYA Biosciences, Inc. | $4.0M | — | NEW | 10.5 |
| 22 |  $LPCN | Lipocine Inc. | $3.6M | 1.4% | -15% | — |
| 23 | $IDYACALL | IDEAYA Biosciences, Inc. | $3.5M | — | NEW | 10.5 |
| 24 |  $IVA | Inventiva S.A. | $3.0M | 1.2% | +78% | — |
| 25 |  $ALXO | ALX ONCOLOGY HOLDINGS INC | $2.9M | 1.2% | NEW | — |
| 26 |  $CNTX | Context Therapeutics Inc. | $2.9M | 1.1% | NEW | — |
| 27 |  $NXTC | NextCure, Inc. | $2.8M | 1.1% | +12% | — |
| 28 |  $AVBPCALL | ArriVent BioPharma, Inc. | $2.5M | — | -67% | — |
| 29 |  $SLGL | Sol-Gel Technologies Ltd. | $2.5M | 1.0% | NEW | — |
| 30 |  $KTTA | Pasithea Therapeutics Corp. | $1.6M | 0.6% | +0% | — |
| 31 | $RLAYCALL | Relay Therapeutics, Inc. | $1.5M | — | NEW | 12.7 |
| 32 |  $TRAW | Traws Pharma, Inc. | $936,437 | 0.4% | -28% | — |
| 33 | $ZNTLCALL | Zentalis Pharmaceuticals, Inc. | $936,000 | — | NEW | — |
| 34 |  $TXMD | TherapeuticsMD, Inc. | $849,250 | 0.3% | NEW | — |
| 35 |  $SPRB | SPRUCE BIOSCIENCES, INC. | $797,270 | 0.3% | -83% | — |
| 36 |  $HOWL | Werewolf Therapeutics, Inc. | $469,199 | 0.2% | NEW | — |
| 37 |  $NEUP | Neuphoria Therapeutics Inc. | $312,283 | 0.1% | NEW | — |
New Positions (19)
$NKTR NEKTAR THERAPEUTICS$9.0M$ANL Adlai Nortye Ltd.$8.8M$ZNTL Zentalis Pharmaceuticals, Inc.$8.5M$SCYX SCYNEXIS INC$7.0M$RLAY Relay Therapeutics, Inc.$6.7M$KALVCALL KalVista Pharmaceuticals, Inc.$6.3M$CCCC C4 Therapeutics, Inc.$5.9M$KPTIPUT Karyopharm Therapeutics Inc.$4.2M$PMN ProMIS Neurosciences Inc.$4.1M$IDYAPUT IDEAYA Biosciences, Inc.$4.0M$IDYACALL IDEAYA Biosciences, Inc.$3.5M$ALXO ALX ONCOLOGY HOLDINGS INC$2.9M$CNTX Context Therapeutics Inc.$2.9M$SLGL Sol-Gel Technologies Ltd.$2.5M$RLAYCALL Relay Therapeutics, Inc.$1.5MExited Positions (15)
$TERN Terns Pharmaceuticals, Inc.
$TARS Tarsus Pharmaceuticals, Inc.
$UPB Upstream Bio, Inc.
$XENE Xenon Pharmaceuticals Inc.
$DBVT DBV Technologies S.A.
$HELP CYBIN INC.
$BLTE BELITE BIO, INC
$VTYX Ventyx Biosciences, Inc.
$VERACALL Vera Therapeutics, Inc.
$WVE Wave Life Sciences Ltd.
$CMPS COMPASS Pathways plc
$AVTX Avalo Therapeutics, Inc.
$ZBIOCALL Zenas BioPharma, Inc.
$NTLACALL Intellia Therapeutics, Inc.
$CLYM Climb Bio, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Squadron Capital Management LLC including:
Track Squadron Capital Management LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Squadron Capital Management LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Squadron Capital Management LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Squadron Capital Management LLC (SEC CIK: 2050709), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Squadron Capital Management LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.